Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H1, 2016


Posted December 8, 2016 by Shirley

“Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H1, 2016″ provides an overview of Cytomegalovirus (HHV-5) Infections clinical trials scenario.

 
MRRS adds "Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H1, 2016" latest studies, published in Nov 2016.

Summary
GlobalData’s clinical trial report, “Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H1, 2016″ provides an overview of Cytomegalovirus (HHV-5) Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Cytomegalovirus (HHV-5) Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope
– The report provides a snapshot of the global clinical trials landscape
– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– Report provides latest news for the past three months

Table of Contents
Table of Contents 2
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Cytomegalovirus (HHV-5) Infections to Infectious Disease Clinical Trials 15
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Cytomegalovirus (HHV-5) Infections to Infectious Disease Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials 29
Prominent Drugs 31
Latest Clinical Trials News on Cytomegalovirus (HHV-5) Infections 32
Feb 21, 2016: Fate Therapeutics to Present Preclinical Data for ProTmune™ at 2016 BMT Tandem Meetings 32
Feb 20, 2016: Chimerix Announces Presentation of Detailed Results From Phase 3 SUPPRESS Trial at BMT Tandem Meetings 32...

List of Tables and Figures
Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials by Region, 2016* 6
Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10
Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11
Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, North America, Top Countries, 2016* 12
Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 13
Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 14
Proportion of Cytomegalovirus (HHV-5) Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2016* 16...

Browse Complete Report with TOC @
http://www.marketresearchreportstore.com/shop/cytomegalovirus-hhv-5-infections-global-clinical-trials-review-h1-2016
Ask a sample or any futher questions, please feel free to contact us:
Tel: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Market Research Report Store
Country United States
Categories Business , Reports , Research
Last Updated December 8, 2016